OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2025-03-31-accounts

Endometriosis UK

Annual report and financial statements for the year ended 31 March 2025

Company no. 02912853 Charity no. 1035810

OSCR no. SC051651

OMETRIOSIS“«

Endometriosis UK Annual Report for year ended 31 March 2025

Contents

For the year ended 31 March 2025

This Trustee and Directors’ report provides an overview of performance in relation to our key objectives and of future plans. It includes key performance data and the stories of some of those Endometriosis UK has helped, in addition to financial summaries and analysis.

Endometriosis UK has helped, in addition to financial summaries and analysis.
Page
Reference and administrative information 2
Trustees’ annual report 4
Independent auditor’s report 26
Statement of financial activities (incorporating an income and expenditure account) 30
Balance sheet 31
Statement of cash flows 32
Notes to the Financial Statements 33

1

OMETRIOSIS“«

Endometriosis UK Annual Report for year ended 31 March 2025

Reference and administrative information

For the year ended 31 March 2025

Endometriosis UK is a company limited by guarantee and a registered charity.

Company number 02912853 Country of incorporation United Kingdom Country of registration England & Wales Charity Number 1035810 Country of registration Scotland Charity Number SC051651

Registered office and operational address 10 – 18 Union Street, London SE1 1SZ

Trustees Trustees, who are also directors under company law, who served during the year and up to the date of this report were as follows:

Liz Campbell Chair Tracey Hammonds Treasurer Catherine Nestor Vice Chair Sanchia Alasia Jenny Bullis Nick Burke Anne Connolly Anna Cooper (Until April 2025) Andrew Horne Emma Prach Cassia Rowland Arvind Vashisht (Until February 2025) Fevzi Shakir (From April 2025)

Endometriosis UK has a skills-based Board of Trustees, and Trustees are recruited in order to ensure that the Board has the right mix of skills and knowledge to provide effective governance. The Board of Trustees has a range of skills and experience including voluntary sector management, fundraising, financial management, primary and secondary health care and of living with endometriosis. Trustees are appointed for a term of three years which is renewable once. Trustees may serve a maximum of six years on the Board.

Company Secretary Emma Cox, CEO Endometriosis UK

Key management personnel Emma Cox, Chief Executive Bankers CAF Bank Limited PO Box 289 Kings Hill West Malling Kent ME19 4TA

2

Endometriosis UK Annual Report for year ended 31 March 2025

Solicitors McDermott Will & Emery 22 Bishopsgate London EC2N 4BQ

Auditor

Godfrey Wilson Limited Chartered Accountants and Statutory Auditors 5[th] Floor Mariner House 62 Prince St Bristol BS1 4QD

Medical Advisory Panel

Kirana Arambage, Consultant Gynaecologist, John Radcliffe Hospital, Oxford

Professor Christian Becker, Senior Clinical Research Fellow, John Radcliffe Hospital, Oxford

Liz Bruen, Endometriosis Specialist Nurse, Cardiff and Vale University Health Board (Until December 2024)

Dr Sharon Dixon, GP and NIHR Doctoral Research Fellow and General Practitioner, Oxford University Emma Evans, Clinical Psychologist, University of Oxford

Professor Andrew Horne, Professor of Gynaecology and Reproductive Sciences, Edinburgh University Shaheen Khazali, Consultant Gynaecologist and Endopelvic surgeon

Dr Uma Marthi, General Practitioner with special interest in women’s health, Rochdale

Dr Veena Rao, General Practitioner with special interest in women’s health, Cumbria (Until April 2025) Fevzi Shakir, Consultant Gynaecologist, Royal Free London

Claudia Tye, Endometriosis Specialist Nurse, Guys and St Thomas

Arvind Vashisht, Consultant Gynaecologist, University College London Hospital

Dr Katy Vincent, Associate Professor, Senior Fellow in Pain in Women, John Radcliffe Hospital, Oxford

Our Medical Advisory Panel provides expert advice and guidance on all our work relating to medical information. A very big thank you for their hard work and dedication in supporting the endometriosis community.

The Trustees present their report and the audited financial statements for the year ended 31 March 2025. Reference and administrative information set out on pages 2 and 3 forms part of this report. The financial statements comply with current statutory requirements, the memorandum and articles of association, the requirements of a directors’ report as required under company law, and the Statement of Recommended Practice - Accounting and Reporting by Charities: SORP applicable to charities preparing their accounts in accordance with FRS 102.

3

OMETRIOSIS“«

Endometriosis UK Annual Report for year ended 31 March 2025

Trustees’ Annual Report

About endometriosis

Endometriosis occurs when cells similar to the ones in the lining of the womb (uterus) are found elsewhere in the body. These cells can grow and change in response to hormones in the menstrual cycle, this can cause inflammation, pain and scar tissue. Endometriosis is most commonly found on the lining of the pelvis (peritoneum) and may occur in the ovaries and involve other pelvic organs, like the bowel or bladder. Less commonly, endometriosis can also be found outside the pelvis, such as in the chest. An estimated 1.5 million women and those assigned female at birth in the UK have endometriosis - that’s 1 in 10 from puberty to menopause who suffer from this disease, although the impact may be felt for life. Whilst for some symptoms are mild, for others it can be debilitating. We currently do not know what causes the disease and there is currently no cure. Common symptoms of endometriosis include pelvic pain, painful periods that interfere with everyday life, heavy menstrual bleeding, pain during or after sex, painful bowel movements, pain when urinating, and difficulty getting pregnant. Symptoms vary from person to person, some may have severe and debilitating symptoms, others may have no symptoms at all. Symptoms are not always related to the location, amount or the type of endometriosis.

Although in the past endometriosis was considered a disease of the over 30s, increasing numbers are reporting that they are experiencing symptoms as early as puberty. Our 2024 diagnosis survey found that 31% were under 16 when they first considered whether symptoms they were experiencing could be due to a medical condition rather than just being “normal”, and when asked to look back with the understanding of endometriosis they have now, this figure increased to 56%. There is no evidence to suggest that this is due to an increase in occurrence of endometriosis, but rather is due to the realisation at an earlier age that severe period pain is not normal. Hence help is being sought at an earlier age.

Whilst there is no cure for endometriosis, treatment and management options aim to reduce the severity of symptoms and improve the quality of life for someone living with the condition. These options are limited, and whilst hormonal treatments can help manage some people’s symptoms, they do not work for everyone, and often the treatment is surgery.

Traditionally, laparoscopic surgery with biopsy has been considered the definitive way of diagnosing endometriosis. However, advances in medical imaging (ultrasound and MRI) are now used by some skilled and trained healthcare practitioners to identify potential endometriosis and plan surgery. It’s important to remember that a negative scan does not rule out endometriosis. Unfortunately, it’s a postcode lottery as to whether you are seen by someone trained in endometriosis and gynaecological imaging, something we’re campaigning to end.

Whilst for some, we know that diagnosis is achieved in a year or less, for many it can take far too long, often with multiple visits to healthcare practitioners before symptoms are recognised. Our latest data shows that it takes on average a shocking 8 years and 10 months to receive a diagnosis, an increase of 10 months since 2020. The data also shows that a worrying 78% of respondents who had received a diagnosis of endometriosis had experienced one or more doctor telling them they were making a ‘fuss about nothing’ or similar comments, and many had the severity of their symptoms questioned by healthcare practitioners. The number of people reporting this experience has increased from 69% in our 2020 survey.

Without a diagnosis and access to treatment, not only can the disease progress, but it may impact every aspect of someone’s life, including physical and mental health, careers, education, and relationships. It’s also important not to forget the impact endometriosis can have on partners, family members and other personal relationships.

All those affected by endometriosis deserve support, and Endometriosis UK exists to provide support for all those affected by the disease and advocate for change so that everyone receives the right support at the right time.

4

Endometriosis UK Annual Report for year ended 31 March 2025 omeTriosis“«

Foreword

Welcome to our 2024-2025 Annual Report, an opportunity to reflect on the incredible year we’ve had and share our exciting future plans .

----- Start of picture text -----
Liz Campbell - Chair
a.
Aas
~
Emma Cox - CEO
----- End of picture text -----

We’d like to start by sharing our heartfelt thanks to everyone who has contributed to the work of Endometriosis UK this year – our volunteers, Trustees, supporters, fundraisers, and staff. It’s only thanks to your efforts that we can continue to provide vital support and drive much needed change to improve the lives of those affected by endometriosis. From running our support services, to courageously sharing your story with the media and cheering on our fundraisers at events - however you support our work, you make a huge difference for all those affected by endometriosis.

Our work would also not be possible without our incredible fundraisers who this year have once again pulled out all the stops to raise money. From the 650 amazing fundraisers who took part in Walk for Endo, to skydives and cake sales – however you were able to raise money for us this year, thank you. Thank you also to everyone who has financially contributed to our work including grants, companies, and trusts.

A huge part of our work this year was to develop our new 2025-2030 strategy, which saw us undertake a thorough process to gather ideas and views from our volunteers, key stakeholders and the endometriosis community.

Before we share with you what’s in our new strategy, let’s take a look back at what you’ve helped us achieve.

Our last five-year strategy saw us achieve a lot – more than doubling our income to £1.5 million which has enabled us to significantly expand our support services and campaigning. Our active volunteer network has grown to almost 200 volunteers, providing invaluable in-person and online support groups, a helpline, webchat, and an online forum. We’ve also campaigned tirelessly for improvements to care across the UK and made as much noise as we could to raise awareness.

At the beginning of 2025 we were able to fulfil a long-held ambition, launching a nurse-led helpline, a step change in the way we provide information and support to the community. In the first quarter, the support line supported over 300 people from the endometriosis community.

Campaigning for change has never been more important for Endometriosis UK, and we remain more determined than ever to see much needed policy changes across various areas including health, education, and employment. We remain deeply concerned that the average diagnosis time in the UK hasn’t reduced in over a decade, and it currently takes on average nearly 9 years to get a diagnosis. Even once a patient receives a diagnosis, there are challenges in accessing treatment and support, and NHS waiting lists remain unacceptably high. We’ve started to make good progress, and this year we have strengthened our relationships with decision makers and health systems in all four nations, helping drive up care standards. Our Chief Executive and our Leicester Support Group Leader, Sunaina Nechel-Maher, sat on the NICE Committee for the NICE Guideline on Endometriosis, and in November, NICE published its updated Guideline – introducing key changes that we hope will improve the baseline of endometriosis care. There have also been several debates on endometriosis in parliaments, and together you wrote over 2,000 emails to parliamentarians to call for much needed change.

This year we have also worked with employers to drive real changes for those with endometriosis in the workplace – breaking down taboos, improving working practices, and working with parliamentarians to call for legislative changes to improve people’s lives at work. Our Menstrual Wellbeing in the Workplace project, funded by the Department for Health and Social Care, also came to a close this year. This project saw us run information

5

Endometriosis UK Annual Report for year ended 31 March 2025

days, webinars, and provide bespoke training and resources for small and medium employers. Although this funding has now come to an end, we continue to work with employers to break down barriers and inspire change in the workplace as part of our Endometriosis Friendly Employer Scheme.

There are now over 100 employers that are part of the Scheme, and we continue to campaign for Governments to introduce key changes to improve HR legislation, as well as working to ensure those who are unable to work don’t face unfair discriminative practices due to their endometriosis.

Supporting research projects also remains a core part of our work, and through the new 2025-2030 strategy, we will do more to ensure patients remain at the heart of endometriosis research. Research provides much needed hope for the future for those with the disease – and we continue to campaign for vital investment in research to find the cause of the disease, better treatment and management options, and one day a cure.

Despite positive progress, we know there is still so much to do to improve the lives of those affected by endometriosis. Over the next year, through our new ambitious strategy, we will continue to provide vital support and campaign for much needed changes to ensure that the 1 in 10 with endometriosis get access to the right care at the right time.

Our new, ambitious strategy reflects the determination of everyone at Endometriosis UK – our volunteers, Trustees, staff, beneficiaries and stakeholders. Those with endometriosis remain at the heart of everything we deliver, and we want to provide the best support and campaign for the best outcomes for those with the disease, at every stage of their lives.

We’d like to end our introduction by thanking our incredible supporters for what you’ve helped us achieve this year. With new research on the horizon and a strategy in place that aims to deliver real change, we hope you’ll stand with us during the year ahead.

Elizabeth Campbell

Emma Cox

Liz Campbell Chair

Emma Cox Chief Executive

6

Endometriosis UK Annual Report for year ended 31 March 2025

Purposes and aims

The aim of the annual report is to review the charity’s aims, objectives, and activities each year, and share with our supporters what you have helped us achieve. We’re incredibly proud of everything we have achieved but know there is much more to do.

The Trustees report the success of each key activity and the benefits the charity has brought to those groups of people that it is set up to help. The review also helps the Trustees ensure the charity's aims, objectives and activities remain focused on its stated purposes.

The Trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the charity's aims and objectives and in planning its future activities. In particular, the Trustees consider how planned activities will contribute to the aims and objectives that have been set.

The charity's key activities and who it tries to help are described below. All its charitable activities are undertaken to further Endometriosis UK’s charitable purposes for the public benefit, and focus on:

The 2020 – 2025 strategy focused on achieving the following outcomes for people living with endometriosis:

Achievements and performance

Key achievements

Support for those living with endometriosis

Delivering support

Our support services remain the lifeblood of Endometriosis UK, and we’re grateful to our volunteers who work tirelessly to provide support services for those who need them.

Our volunteer-led support services - which includes online and in person support groups, a helpline, webchat, and online forum Health Unlocked - delivered support to 14,345 people this year. We have also trained 73 new volunteers, with our total number of active volunteers at the end of March at 191, and we launched 10 new support groups this year across the UK.

7

ometRiosis«

Endometriosis UK Annual Report for year ended 31 March 2025

This year we are also thrilled to have launched our new Nurse-led Support Line, staffed by endometriosis clinical nurse specialists, offering much-needed support and information to those with endometriosis across the UK. With less than 30% of those with endometriosis in the UK having access to a specialist nurse, we understand the vital need and high demand for this service.

The service brings expert compassionate support including advice on managing endometriosis, understanding symptoms and exploring treatment options. In the first quarter, the support line supported over 300 people from the endometriosis community.

During the year, we built on our Equality, Diversity and Inclusion (EDI) work, and one key strand was Endometriosis UK celebrating Pride. We held information stands at seven Pride events across the UK in 2024, spreading awareness, offering advice, and making new connections with LGBTQ+ organisations across the country. We believe that everyone affected by endometriosis should have access to support, and Endometriosis UK is dedicated to being there for everyone. Together we are working with others to ensure that we are a safe space for all those affected by endometriosis.

All volunteers, as well as staff, are required to adhere to Endometriosis UK’s safeguarding policy, which aims to protect vulnerable people across all aspects of our work.

Highlights of the last year include significant increases in the number of support group meetings held, calls to our volunteer-led helpline and digital support services:

Support groups

8

Endometriosis UK Annual Report for year ended 31 March 2025

Our new Nurse-led Support Line launched in January 2025, and we’ve already started to see the benefit in how it is supporting the community. Already since the service launched in January 2025 until March 2025, the service has supported:

Volunteer-led helpline:

Supporting our volunteers

Throughout the year we supported our amazing and dedicated team of volunteers, who do so much to help the endometriosis community and provide peer support.

This year we worked on developing a new e-learning module for volunteers providing core information and training in an accessible format.

We recruited and delivered induction training to all our new volunteers. We also provided volunteers access to media training, safeguarding training, and support skills training.

We also held our first Trustee, volunteer and staff conference day, which brought together volunteers, Trustees, and staff in Birmingham. This was an incredible opportunity to come together and reflect on our shared values and ambitions for the future. We couldn’t achieve what we do without our incredible volunteers and having the opportunity to come together to meet and say thank you was a real highlight of the year.

9

OMETRIOSIS“«

Endometriosis UK Annual Report for year ended 31 March 2025

Future plans:

Providing high quality and up to date information

This year, we developed and launched an online Symptom Checker , to help those with suspected endometriosis have better discussion with their GPs, access appropriate referrals and support, and speed up diagnosis. Our Symptom Checker is simple to use, take you through some questions and generates a letter for your GP along with information about relevant guidance such as the NICE Guideline on Endometriosis. The symptom checker has had 199,224 views since launching and remains our most viewed page on the website. In the first month, it had 21,000 views.

We continued to work on improving the accessibility of our information, conducting a comprehensive health literacy review of all our print and online health materials. We look towards completing our Patient Information Forum TICK accreditation and have embedded those principles into our new Information Production Process.

We also developed and reviewed new information resources this year including:

We’d like to say a special thank you to Cysters for working with us to ensure everyone’s voices are heard.

Future plans:

Supporting people with endometriosis in the workplace

Our Endometriosis Friendly Employer Scheme (EFE) offers a way for employers to confirm their commitment to developing a work environment and culture that enables employees with endometriosis to thrive at work.

The scheme continues to grow, and we have over 140 organisations joining the pledge, including major employers and household names such as British Airways, Hargreaves Lansdown, Nationwide Building Society, NHS Ayrshire and Arran, The Welsh Parliament, Scotrail, The University of Manchester, and many more.

We developed the EFE scheme in response to all the feedback we get on the impact of endometriosis at work. To further provide support in this important area, maximising the potential of the scheme and developing our work with employers, we invested in a dedicated Endometriosis Friendly Employer Scheme Manager at the end of last financial year. We look forward to continuing to grow the scheme and expand the resources and guidance we offer to our members and employers, ensuing more employees with endometriosis can thrive at work.

Building on the success of our Endometriosis Friendly Employer (EFE) Scheme, the last two years has seen us deliver a Workplace Menstrual Wellbeing Project, focused on supporting and guiding small and medium-sized businesses (SMEs) to create a working environment that is supportive of those with menstrual health conditions. The two year project, which ended in March 2025, aimed to raise awareness about menstrual health and support SMEs with training and resources. It focused on helping workplaces understand menstrual health, support

10

Endometriosis UK Annual Report for year ended 31 March 2025

employees, and build an inclusive culture. The goal was to educate people about conditions like endometriosis, PCOS, adenomyosis, fibroids, heavy periods, and PMDD (premenstrual dysphoric disorder). The project included webinars, events, and educational materials to help employers and employees feel more confident talking about menstrual health and creating supportive policies at work. The webinars were a big success, with over 6,000 views. Employers who attended the in-person information days gave positive feedback, saying they felt supported and left with useful information they could use to make changes in their own organisations to better support staff with menstrual health conditions.

Research

We were delighted to be partners in a successful consortium bid for a major EU Horizon Fund grant. The EUmetriosis project is a multi-country project that aims to address unmet needs related to endometriosis and advance patient care. It combines social research, clinical research, and patient and public involvement (PPI), and will run for 5 years. Endometriosis UK is leading on PPI along with our sister associations in the Netherlands and Croatia, plus on public communications. More details can be found on our website, and the new EUmetriosis website.

We are pleased to be involved in a range of research projects. Research into endometriosis is vital to find out more about the disease. Only through research will we find out more about the cause of endometriosis, how to better treat and manage it, the support people might need, and, one day, a cure. We have partnered with university researchers and clinical trials teams to aid recruitment and participation in a number of research projects aimed at improving the lives of those living with endometriosis.

During the year, we provided support for a range of research applications. For some we are co-investigators on the projects, ensuring the voice of those with endometriosis is at the heart of the research being developed. We have provided advice, undertaken surveys, reviewed materials and written letters of support for a number of applications, some of which take several months to hear an outcome. It has been a challenging time for clinical trials and medical research into endometriosis, with the long delays and waiting times for appointments and surgery impacting on activities that can take place. We continue to work closely with other research teams to support their activities and recruitment.

Future plans:

11

OMETRIOSIS“«

Endometriosis UK Annual Report for year ended 31 March 2025

Awareness and campaigning

Raising your voices with Governments

To drive real change for those with endometriosis, we continue to step up our campaigning and awareness raising initiatives. The voices of those with endometriosis are at the heart of all our work, and our policy, campaigns and awareness raising work is no exception. This includes working with our supporters to respond to policy consultations, build relationships with politicians across the UK, creating opportunities for supporters to write to their elected representatives to call for change, and by sharing people’s personal stories with the media.

The UK General Election held in July 2024 provided us with an exciting opportunity to engage a new set of MPs in our work, and ensure every MP knows what endometriosis is and what changes are needed to ensure everyone gets access to the right care at the right time. Ahead of the election, over 500 supporters lobbied their election candidates to ask them to commit to raising the voices of those affected by endometriosis if elected, and soon after the election we called on MPs to get straight to work to ensure endometriosis remains on the policy agenda. Supporters once again lobbied their newly elected MPs, and we created a campaign pack for any supporter who met with their MP to call for change. As a result of our supporter campaigning, since the election, endometriosis has been mentioned by parliamentarians across both the House of Commons and the House of Lords 96 times.

We have contributed to numerous parliamentary debates and policy reports that have been published this year. We provided evidence to the Women and Equalities Committee Inquiry into Reproductive Health Conditions, which resulted in a series of recommendations by the Government. This included a commitment to stop using the term ‘benign gynaecology’, a term often used by healthcare practitioners, which undermines the severity of the disease, a change which Endometriosis UK campaigned for alongside the Royal College of Obstetricians and Gynaecologists, and improved education for healthcare practitioners on menstrual health.

This year saw new research published by the Office for National Statistics (ONS) highlighting the negative impact endometriosis can have on earnings for those with the disease, and an NHS Confederation Report, highlighting a whopping £11bn a year being the estimated economic cost just for absenteeism due to severe period pain and heavy periods, alongside endometriosis, fibroids and ovarian cysts – helping us create a robust economic case to Governments that simply cannot afford to be ignored. Endometriosis UK was involved with and contributed to both projects.

Responding to policy consultations also remains a key part of our influencing work. We have responded to numerous consultations including the Spending Review, Plan to Make Work Pay, RSHE guidelines, Fit Note reform, NHS 10 Year Health Plan, and the Curriculum and Assessment Review. We continue to engage our supporters to ensure policy consultations reflect the needs of the community, for example in April 2024 we received over 1,000 responses to a survey about the previous governments plan to change fit notes, giving us valuable information about the community’s challenges in the workplace.

12

OMETRIOSIS“«

Endometriosis UK Annual Report for year ended 31 March 2025

We’ve pushed to drive up care standards and quality of care offered to people affected by endometriosis across all four nations. This year we played an instrumental role in the partial update of the NICE Guideline on Endometriosis, firstly campaigning to get the Guideline reviewed, and with our CEO being selected to sit on the review Committee, as well as Endometriosis UK’s Leicester Support Group Leader, Sunaina Nechel-Maher. The section on diagnosis was updated and published in November 2024. Key changes included a recommendation that a transvaginal ultrasound scan should be offered to all those with suspected and confirmed endometriosis, improvements to diagnosis, access to treatment, and more holistic approaches to supporting the management of endometriosis. Whilst we were pleased to be involved in the partial review, we continue to call for both the implementation of the Guideline and a full review of the Guideline which we believe has significant gaps in the care pathway.

We continue to work closely with the Scottish Government on the implementation of the Women’s Health Plan, and in Wales we are delighted to have seen the launch this year of the Women’s Health Plan for Wales which recognises the seriousness of and prioritised endometriosis and adenomyosis. We will continue to work in Wales and Scotland to ensure the actions promised in these Plans become a reality.

In Northern Ireland, we have prioritised strengthening relationships with MLAs and have contributed to a number of stakeholder events and sessions on the ongoing work to introduce a Women’s Health Plan. We joined the All-Party-Group on Women’s Health and have delivered two presentations on endometriosis to the Group, including representatives of the Department for Health and Social Care.

Across all four nations, we hosted in-person events during Action Month, reaching a record number of parliamentarians. During the month, over 100 parliamentarians attended events, we directly engaged with 452 political representatives, and 22 questions and devolved equivalents were raised across all four nations during the month on endometriosis.

Following the UK General Election, we were delighted to play a key role in relaunching the APPG on Endometriosis in Westminster, and continue to provide Secretariat to the All-Party-Parliamentary-Group (APPG) on Endometriosis in Westminster, and the Cross-Party Group (CPG) on Women’s Health in Scotland, working to brief politicians and Peers on key issues affecting those with endometriosis – including on health, education and employment.

13

Endometriosis UK Annual Report for year ended 31 March 2025

Our campaigning work has been recognised this year by supporters and parliamentarians: MPs in Parliament have also celebrated our work. Gill Furniss MP said in Parliament on 15[th] January 2025:

The Minister for Secondary Care, Karin Smyth also said in Parliament on 15[th] January 2025

The Minister for Women’s Health in Scotland, Jenni Minto, at our annual Action Month reception also said:

Raising awareness with the media and across digital channels

We are incredibly grateful to those with endometriosis who have bravely shared their story with the media, and in total this year there have been over 200 pieces of news coverage referencing Endometriosis UK across print outlets including The Guardian, BBC News, The i newspaper, Vogue, Cosmopolitan, and Grazia magazine. We also continue to work with specialist media such as the Pharmacist, HR outlets and Pulse Magazine to ensure our reach continues to grow.

We’ve also been proud to be part of numerous broadcast pieces, including on the BBC Breakfast sofa discussing gynaecology waiting times, Women’s Hour to discuss endometriosis treatments, and over 50 radio pieces featuring either an Endometriosis UK Spokesperson or one of our incredible volunteers sharing their lived experience.

Over 300 stories have been submitted on our share your story form, and we continue to put people’s stories at the heart of our media work to raise awareness, break down barriers, and drive change.

Our website received a total number of 1.9 million individual user views, up by 146% on last year. Our most visited pages include our newly launched symptom checker which has been visited 200,000 times, and our information and support pages. Our social media continues to be a place to educate, break taboos, and inform people about endometriosis, the symptoms, and its impact. Our channels continue to grow, and this year our platforms reached over 6 million users across all platforms, with our Tik Tok videos viewed more than 200% on the previous year. Thank you to everyone who shares their story on our platforms as well as our social media posts.

14

OMETRIOSIS“«

Endometriosis UK Annual Report for year ended 31 March 2025

Action Month in March remains a key month in the endometriosis calendar, and every year we are blown away by the commitment and support from our community. This year was no exception, and our theme “Endometriosis Explained” aimed to explain what endometriosis is, its impact, and how we can all work together to empower change. Highlights for Action Month this year included: reaching over 1 million people across our social media platforms; delivering over 40 talks to employers; 1,225 emails sent by supporters to their elected representatives; supported 46 volunteer led events; and 137 articles referenced endometriosis.

Future plans:

One supporter said about our campaigning work:

15

OMETRIOSIS“«

Endometriosis UK Annual Report for year ended 31 March 2025

Resourcing

We’ve continued to work to deliver our five-year strategic plan, strengthening our ambitions and resolve to ensure everyone living with endometriosis has a prompt diagnosis, high quality care and the support they need.

Our staff team grew further this year, with new permanent roles allowing us to increase the amount of work we can do. As new staff settle in, we look forward to being able to deliver more for the endometriosis community in the year ahead.

We have continued to diversify our income and have had another great year for Community Fundraising, corporate donations, and gifts in wills. We were delighted to receive support from a number of funders and partners including The National Lottery, Bloomberg, the Department of Health and Social Care, Lil-lets, Simply Health, and Time of the Month (TOTM). This support has contributed to the running of our much-needed support services, including volunteer training and resources, our information provision as well our new Specialist Nurse Helpline and our awareness raising activities.

16

OMETRIOSIS“«

Endometriosis UK Annual Report for year ended 31 March 2025

Future plans

Supporters

We fundraise in diverse ways alongside raising as much awareness as possible, our main fundraising activities include:

We are incredibly grateful to our community of supporters who make our work possible. Over 650 people participated in our flagship challenges Walk for Endo, Winter Walk for Endo, Go Yellow! Endo the Night and Tea for Endo, and the 1in10 Challenge, raising over £116,000. Action Month saw a real boost in workplace fundraising with 64 workplaces putting on fundraising events which helped to raise awareness, break taboos and tackle stigma. We were delighted to see staff from household names such as British Airways, Marks and Spencer Head Office, HMRC, and Deloitte LLP hosting events such as Tea for Endo and Go Yellow!

In addition to these events, many others fundraised for us by participating in their own events or found new and creative ways to fundraise. Highlights include a supporter from Wales who raised over £18,000 by hosting an afternoon tea, charity walk and a gala dinner, and another amazing supporter raised over £12,000 by participating in a 220 mile walk from Broadstairs to Glastonbury in memory of his friend. A group of dedicated endometriosis consultants and trainees cycled from Manchester to Belfast in aid of Endometriosis UK, raising over £15,000 and lots of awareness along the way. We were delighted to be selected as charity of the year for the annual Women of Scotland Lunch. Our amazing team of Scotland based volunteers were there on the day

17

OMETRIOSIS“«

Endometriosis UK Annual Report for year ended 31 March 2025

to help make it a success and we were honoured to have HRH Sophie Duchess of Edinburgh in attendance. The lunch raised £30,000 to go towards our support activities in Scotland.

It was a fantastic year for Challenge Event fundraising; we doubled our income compared to last year, raising over £250,000 with almost 300 participants taking part in a range of events. We had places in the Great North Run, Asics 10k, Royal Parks Half Marathon, Cardiff Half Marathon, London Landmarks Half Marathon, Brighton Marathon, Edinburgh Marathon, and many more. Despite having no charity spaces in the London Marathon, we were fortunate enough to have 20 people with open ballot spaces running in aid of Endometriosis UK.

In October, we participated in The Big Give Women and Girls Match Funding Campaign and were delighted to have exceeded our target of £20,000. The campaign focused on launching our new Specialist Nurse Helpline, and we were grateful to all who donated.

As a supporter-focused charity, we understand that all our achievements to support those impacted by endometriosis would not be possible without the generosity of our amazing supporters. We are committed to fundraising in an honest and transparent way. We are registered with the Fundraising Regulator and pay an annual levy to support its work. We adhere to the Code of Fundraising Practice and our supporter promise remains at the heart of all our fundraising.

When fundraising for Endometriosis UK you can be sure that:

At Endometriosis UK we have not engaged any professional fundraisers to raise funds on behalf. The charity established Commercial Participator Agreements with all sole traders and businesses known to be fundraising for Endometriosis UK and monitored the activities of those fundraising by reviewing proposed messaging and products, and social media monitoring. There were no known failures to comply with the code of the Fundraising Regulator, and no complaints were received regarding staff, volunteers or individuals fundraising for Endometriosis UK. Our fundraising activities are closely monitored by the Finance Committee, which reports to our Board of Trustees.

Future plans

18

Endometriosis UK Annual Report for year ended 31 March 2025

Beneficiaries of our services

Our beneficiaries include all those with or impacted by endometriosis.

Endometriosis UK is committed to supporting and advocating for everyone affected by endometriosis regardless of race, gender, sex, gender identity, class, sexual orientation or disability and ensuring diversity. Everyone affected by endometriosis needs to be acknowledged, and we know that we must do more to identify the needs of all those affected by endometriosis, develop, maintain, and evaluate our work to meet those needs and advocate for necessary change and ensure all voices are heard. We know that there are additional complexities in accessing healthcare and support for those from Black, Asian and minority ethnic communities, and for the LGBTQ+ community.

We are taking steps to actively ensure we drive change for those from under-represented groups. The Board’s Diversity & Inclusion Group continues to take this work forward. We have recruited a Community and Involvement Officer to build relationships and seek out partnerships with grassroots, community and faith-based groups across London. We have also continued to grow our EDI Forum, recruiting from a diverse group of volunteers to act as critical friends to the organisation. We’d like to say a huge thank you to Cysters, who have supported our work in helping us understand the challenges faced by marginalised groups and amplify the voices of everyone in the endometriosis community. Their work is invaluable in supporting Endometriosis UK’s work.

Finances and Governance

Financial review

The Board of Trustees oversees the charity’s finances. To support the Board, the Finance Committee meets regularly, chaired by our Treasurer.

For the financial year 2024/25 we planned a significant increase in our expenditure so that we could improve support to the endometriosis community and have a louder voice for the community. We were able to do this due to increasing income over prior years and building our reserves, enabling sustainable expansion.

Income increased significantly this year from £1,219,730 in 2023/2024 to £1,506,848 for this reporting year.

Expenditure increased to £1,439,524 in 2024/25, up from £1,167,069 in 2023/24. Planned spending was undertaken focusing on where we identified most long-term impact for our beneficiaries, notably around our helplines and support services, and information services.

Expenditure is regularly reviewed and carefully monitored. New expenditure and projects included launching the new Specialist Nurse Helpline and investing in our Endometriosis Friendly Employer Scheme. With increasing staff, we expanded our office space within the Royal College of Obstetricians and Gynaecologists building. At the Royal College we are part of a hub for women’s health charities enabling us to work collaboratively more easily with the Royal College and other charities with similar interests. Further expansion of our work is planned over the next year, including development of our information provision, expanding our support network, and increasing our campaigning and awareness work. Despite the increase in expenditure, we generated a surplus of £67,324 due to the amazing fundraising from our supporters and the increased skill of our fundraising staff team.

The main increases were in the following areas:

19

OMETRIOSIS“«

Endometriosis UK Annual Report for year ended 31 March 2025

The Trustees aim to secure diverse income streams to ensure our income is sustainable and more resilient to changes in the external environment. In this way we can achieve our objectives – we have ambitious plans. Through both managing costs and developing our fundraising, the Trustees carefully monitored finances over the year to ensure the year ended with unrestricted reserves that comfortably met our reviewed reserves policy. As part of our planned growth strategy, we have grown our reserves which enabled us to grow the organisation over the last five years in a sustainable way. Having reserves enabled us to survive the initial impact of Covid-19 and undertake managed growth through the pandemic and the more recent cost of living crisis. We want to continue to grow so we can do more to support all those with endometriosis. The Trustees, working closely with the CEO, will continue to look for opportunities to develop further fundraising opportunities along with how best to spend our income to deliver the most for those with endometriosis.

Principal risks and uncertainties

The charity reviews risks on a regular basis and uses a risk-based management approach to decision making. This continued in 2024-25, covering the key aspects of our work including finance, governance and management, operational, and external factors. Material risks were identified, reviewed and mitigated by the Trustees and this will continue in the year ahead. Time was spent examining strategic risks in the external environment and reviewing the strategic plan against these.

Our risk statement was reviewed, and our risk register updated. The risk register is reviewed on a regular basis by staff and Trustees. A range of five-year scenarios and financial modelling was undertaken to enable the Trustees to plan how to manage the charity, monitor progress and mitigate risks. Expenditure continues to be carefully monitored given uncertainty about fundraising income in the challenging economic climate.

Our key risks, and our mitigations for these, are:

Reserves policy and going concern

Our reserves policy is to hold unrestricted reserves equivalent to at least six months’ operating costs. We hold financial reserves for practical reasons, including:

20

Endometriosis UK Annual Report for year ended 31 March 2025

As detailed above, our reserves have increased this year which will support the expansion of our work and ensure our sustainable growth. Free reserves as of 31st March 2025 were £1,008,499. This equates to seven months of operating costs for the financial year taking account of designated funds which have been set aside for committed future projects. £42,262 of restricted funds were carried forward. We started the year in a good financial position, having worked hard over prior years to build reserves in order to expand our activities. We have cautiously expanded to ensure sustainability, with expenditure minimised whilst we ascertained the impact of inflation and cost of living challenges. The reserves level achieved is based on meeting our reserves policy over the next year as the charity grows.

We would like to thank all of our fundraisers, donors and partners who were so generous over the year.

The Trustees have reviewed the level of reserves and available liquid resources in the context of plans over the next 12 months, the five-year financial scenario plans, and the organisational risk assessment. The Trustees believe that Endometriosis UK has sufficient financial resources to continue in operational existence for the foreseeable future and that we are well placed to manage its operating risks successfully. They have therefore continued to adopt the going concern basis of accounting in preparing the annual financial statements.

Structure, governance and management

Endometriosis UK is a charitable company limited by guarantee, incorporated on 25th March 1994 and registered with the Charity Commission as a charity on 29th March 1994. The company was established under a Memorandum of Association which established the objects and powers of the charitable company and is governed under its Articles of Association. In March 2021, we registered with OSCR - the Scottish Charity Regulator.

The Board of Trustees has three sub committees, Finance, Diversity and Inclusion, and Nominations. These operate to agreed Terms of Reference and with limited delegated powers from the Board.

The recruitment of Trustees is framed by an audit of the skills held by the members of the Board. Trustees are appointed by an open recruitment process using both search and advertisement as appropriate, against an agreed person profile and job specification. Shortlisted candidates are interviewed by a Nominations Committee of the Board who make a recommendation to the Board. The AGM of the Charity confirms all appointments.

All Trustees give their time voluntarily and receive no benefits from the charity. Any expenses reclaimed from the charity are set out in note 9 to the accounts.

During the year we tendered for and appointed new auditors.

Trustee induction and training

The Board hold an annual away day to consider strategy and review the performance of the Board. Following this, an in-depth strategy development process was undertaken, and a new strategy for 2025 – 2030 developed.

During the year, the Board undertook an audit to ensure there remains the necessary skills and experience to lead the charity effectively. Opportunities for training and knowledge development are raised with the Board, for example the training offered by auditors.

21

Endometriosis UK Annual Report for year ended 31 March 2025

Risk Management

The Trustees have a Risk Policy and a Risk Register. Each Board meeting assesses whether new risks have emerged or whether any of the identified risks have changed in severity. The whole risk register was reviewed at the September and November Board meetings. Trustees consider that the formulated plans to deal with such risks are appropriate at present.

Remuneration policy for key management personnel

The salary of the CEO is agreed by the Board of Trustees, taking into account benchmarking across the sector, performance against objectives, and market conditions. Our work is dependent on voluntary donations and we act in an open and transparent way that respects the money, time and energy given by donors and volunteers. In our commitment to openness, we disclose information about the CEO’s salary within our annual report, as recommended by the National Council for Voluntary Organisations (NCVO).

Statement of responsibilities of the Trustees

The Trustees (who are also directors of Endometriosis UK for the purposes of company law) are responsible for preparing the Trustees’ annual report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England and Wales requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the Trustees are required to:

The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended). They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Trustees are aware:

Members of the charity guarantee to contribute an amount not exceeding £1 to the assets of the charity in the event of winding up.

22

Endometriosis UK Annual Report for year ended 31 March 2025

Auditor

Godfrey Wilson was appointed as the charitable company’s auditor at the AGM in November 2024.

The Directors annual report has been prepared in accordance with the special provisions applicable to companies subject to the small companies' regime.

The Trustees’ annual report has been approved by the Trustees on 15[th] September 2025 and signed on their behalf by

Elizabeth Campbell

Liz Campbell Tracey Hammonds Chair Treasurer

23

Endometriosis UK Annual Report for year ended 31 March 2025

Acknowledgements

We could not do the work we do without the time and knowledge kindly offered to us by our volunteers, fundraisers, speakers, health experts and medical advisors. Without them, we would not be able to reach and support the people we do. We would like to thank them all for their on-going support and generosity.

All those volunteers who have given up their time to support people affected by endometriosis - through the Helpline, Support Groups, Webchat, and Health Unlocked - receive a special vote of thanks. A huge thanks as well to everyone who took on a challenge event or hosted their very own fundraising project to raise money to support the charity.

And a very heartfelt thank you to those who told their stories to the media to raise awareness, which can be such a hard and emotional thing to do yet is vital in raising awareness and helping others.

We are very aware of the significant inequalities faced by those from marginalised communities in accessing care. We are determined to turn this around, and thank you to the charity Cysters and founder Neelam HeeraShergill, for partnering with us and supporting us on this journey.

As always, all of our work will be a team effort. Our staff, volunteers, members, Trustees, those with endometriosis in our wider community, their friends and family, healthcare professionals, researchers – all of those who work so tirelessly as part of Team Endometriosis are making a huge difference where it is so desperately needed. We are grateful to those organisations who have provided expertise and support to help us raise awareness.

We are extremely grateful for the continued and new support of the funders below. We would also like to thank every individual and group who has made a donation and encouraged others to support and fundraise for us this year. We would also like to thank our small and dedicated staff team.

With a thank you to our funders 2024-2025:

  1. AMW Charitable Trust

  2. Bernard Gold Foundation

  3. Batchworth Trust

  4. Barratt Foundation

  5. The Give Women and Girls Match Fund

  6. Bloomberg

  7. Cecil Pilkington Charitable Trust

  8. Costa Coffee Community Grants

  9. Curtis Charitable Trust

  10. Department of Health and Social Care

  11. Eddleston Settlement

  12. Edgar E Lawley Foundation 13. Edrington 14. Ethel and Gwynne Morgan Trust

  13. Fusion 21

  14. Garfield Weston

  15. Grace Trust

  16. Hospital Saturday Fund

  17. Lil-lets

  18. Masonic Charitable Foundation

  19. Maximus Foundation UK

  20. National Lottery Community Fund

  21. Peter John Foord Charitable Trust

24

Endometriosis UK Annual Report for year ended 31 March 2025

  1. Pilkington Charities Fund 25. RS Brownless Trust 26. Robertsons Trust 27. ShareGift 28. Simply Health 29. Squire Patton Boggs Charitable Trust 30. TK Maxx and Homesense Foundation 31. TOTM 32. Vandervell Foundation 33. Villagers 34. Vitol Foundation 35. Westfield Health 36. Whitaker Charitable Trust

We would also like to thank McDermott, Will and Emery who provide pro bono legal advice and services to Endometriosis UK. Their help has been invaluable in helping us progress our work as a charity.

Get involved

The more people working together the stronger we are and the louder our voice. We have a range of ways you can get involved, for more information please check out our website: www.endometriosis-uk.org/get-involved.

If you would like to hear what we are up to throughout the year, sign up for our regular e-update.

Contact

Endometriosis UK 10 -18 Union Street, London SE1 1SZ Tel: 020 7222 2781 Helpline: 0808 808 2227 www.endometriosis-uk.org/contact-us

Instagram endometriosis.uk Facebook www.facebook.com/endometriosis.uk.org X @EndometriosisUK

25

Independent auditors' report

To the members and the trustees of

Endometriosis UK

Opinion

We have audited the financial statements of Endometriosis UK (the 'parent charity') and its subsidiary (the 'group') for the year ended 31 March 2025 which comprise the consolidated statement of financial activities, consolidated and parent charity balance sheets, consolidated statement of cash flows and the related notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102: The Financial Reporting Standard applicable in the UK and the Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the group and parent charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and the provisions available for small entities, in the circumstances set out in note 9 to the financial statements, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group and parent charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor’s report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

26

Independent auditors' report

To the members and the trustees of

Endometriosis UK

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinion on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and parent charity and their environment obtained in the course of the audit, we have not identified material misstatements in the directors’ report included within the trustees’ report. We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 and the Charities Accounts (Scotland) Regulations 2006 requires us to report to you if, in our opinion:

Responsibilities of the trustees

As explained more fully in the trustees’ responsibilities statement set out in the trustees’ report, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the group and the parent charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or the parent charity or to cease operations, or have no realistic alternative but to do so.

27

Independent auditors' report

To the members and the trustees of

Endometriosis UK

Our responsibilities for the audit of the financial statements

We have been appointed as auditor under section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with the Acts and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The procedures we carried out and the extent to which they are capable of detecting irregularities, including fraud, are detailed below:

(1) We obtained an understanding of the legal and regulatory framework that the group and parent charity operates in, and assessed the risk of non-compliance with applicable laws and regulations. Throughout the audit, we remained alert to possible indications of non-compliance.

(2) We reviewed the group and parent charity’s policies and procedures in relation to:

(3) We inspected the minutes of trustee meetings.

(4) We enquired about any non-routine communication with regulators and reviewed any reports made to them.

(5) We reviewed the financial statement disclosures and assessed their compliance with applicable laws and regulations.

(6) We performed analytical procedures to identify any unusual or unexpected transactions or balances that may indicate a risk of material fraud or error.

(7) We assessed the risk of fraud through management override of controls and carried out procedures to address this risk. Our procedures included:

28

Independent auditors' report

To the members and the trustees of

Endometriosis UK

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. Irregularities that arise due to fraud can be even harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council’s website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.

Use of our report

This report is made solely to the charity’s members, as a body, in accordance with Chapter 3 of part 16 of the Companies Act 2006, and to the charity’s trustees, as a body, in accordance with Regulation 10 of the Charities Accounts (Scotland) Regulations 2006. Our audit work has been undertaken so that we might state to the charity’s members and trustees those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity, the charity's members as a body and the charity’s trustees as a body, for our audit work, for this report, or for the opinions we have formed.

William Guy Blake

Date: 22 September 2025

William Guy Blake ACA (Senior Statutory Auditor)

For and on behalf of:

GODFREY WILSON LIMITED

Chartered accountants and statutory auditors 5th Floor Mariner House 62 Prince Street Bristol BS1 4QD

29

Endometriosis UK

Consolidated statement of financial activities (incorporating an income and expenditure account)

For the year ended 31 March 2025

Restricted
Note
£
Income from:
Donations and legacies
4
-
Charitable activities
5
257,984
Other trading activities
6
-
Investments
-
Total income
257,984
Expenditure on:
Raising funds
-
Charitable activities
Helpline and support services
304,692
Information services
-
Research
-
Total expenditure
8
304,692
(46,708)
Reconciliation of funds:
Total funds brought forward
97,404
Total funds carried forward
50,696
Net income / (expenditure) and net
movement in funds		 Unrestricted
£
662,417
-
561,968
24,479
1,248,864
224,582
475,154
395,097
39,999
1,134,832
114,032
1,256,903
1,370,935		 2025
Total
£
662,417
257,984
561,968
24,479
1,506,848
224,582
779,846
395,097
39,999
1,439,524
67,324
1,354,307
1,421,631		 Restated
2024
Total
£
464,641
282,624
453,449
19,016
1,219,730
192,569
630,652
313,174
30,674
1,167,069
52,661
1,301,646
1,354,307

All of the above results are derived from continuing activities. There were no other recognised gains or losses other than those stated above. Movements in funds are disclosed in note 19 to the accounts.

Income has been restated in the prior year to reclassify income between donations and other trading activities, as explained in note 2. This has no impact on net income.

30

Endometriosis UK

Consolidated balance sheets

As at 31 March 2025

Note
Fixed assets
Tangible assets
12
Current assets
Debtors
15
Cash at bank and in hand
Liabilities
16
Net current assets
Net assets
18
Funds
19
Restricted funds
Unrestricted funds
Designated funds
General funds
Total charity funds
Creditors: amounts falling due
within 1 year		 The group
2025
£
53,537
32,776
1,510,504
1,543,280
(175,186)
1,368,094
1,421,631
42,262
317,333
1,062,036
1,421,631		 The group
2024
£
34,417
39,899
1,374,262
1,414,161
(94,271)
1,319,890
1,354,307
97,404
238,000
1,018,903
1,354,307		 The charity
2025
£
53,537
32,847
1,508,681
1,541,528
(175,186)
1,366,342
1,419,879
42,262
317,333
1,060,284
1,419,879		 The charity
2024
£
34,417
39,705
1,372,826
1,412,531
(94,484)
1,318,047
1,352,464
97,404
238,000
1,017,060
1,352,464

These accounts have been prepared in accordance with the special provisions applicable to companies subject to the small companies' regime.

Approved by the trustees on 15 September 2025 and signed on their behalf by

Elizabeth Campbell

Liz Campbell - Chair

31

Endometriosis UK

Consolidated statement of cash flows

For the year ended 31 March 2025

Cash used in operating activities:
Net movement in funds
Adjustments for:
Depreciation charges
Dividends and interest from investments
Decrease in debtors
Increase in creditors
Net cash provided by operating activities
Cash flows from investing activities:
Dividends and interest from investments
Purchase of tangible fixed assets
Net cash provided by / (used in) investing activities
Increase in cash and cash equivalents in the year
Cash and cash equivalents at the beginning of the year
Cash and cash equivalents at the end of the year		 2025
£
67,324
10,773
(24,479)
7,123
80,915
141,656
24,479
(29,893)
(5,414)
136,242
1,374,262
1,510,504		 2024
£
52,661
12,543
(19,016)
36,192
44,189
126,569
19,016
(8,947)
10,069
136,638
1,237,624
1,374,262

The charity has not provided an analysis of changes in net debt as it does not have any long term financing arrangements.

32

Endometriosis UK

Notes to the financial statements

For the year ended 31 March 2025

1. Accounting policies

a) General information and basis of preparation

Endometriosis UK is a charitable company limited by guarantee registered in England and Wales. The registered office address is 10-18 Union Street, London, England, SE1 1SZ.

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities in preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Endometriosis UK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note.

b) Group accounts

These financial statements consolidate the results of the charitable company and its whollyowned (controlled) subsidiary on a line by line basis. Transactions and balances between the charitable company and its subsidiary have been eliminated from the consolidated financial statements. Balances between the two companies are disclosed in the notes of the charitable company's balance sheet. A separate statement of financial activities, or income and expenditure account, for the charitable company itself is not presented because the charitable company has taken advantage of the exemptions afforded by section 408 of the Companies Act 2006.

c) Going concern basis of accounting

The accounts have been prepared on the assumption that the charity is able to continue as a going concern, which the trustees consider appropriate having regard to the current level of unrestricted reserves. There are no material uncertainties about the charity's ability to continue as a going concern.

d) Income

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the item of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Income from the government and other grants, whether 'capital' grants or 'revenue' grants, is recognised when the charity has entitlement to the funds, any performance conditions attached to the grants have been met, it is probable that the income will be received and the amount can be measured reliably and is not deferred.

For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the Trust that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have been met, then the legacy is treated as a contingent asset and disclosed if material.

33

Endometriosis UK

Notes to the financial statements

For the year ended 31 March 2025

1. Accounting policies (continued)

e) Donated services and facilities

Donated professional services and donated facilities are recognised as income when the charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use by the charity of the item, is probable and the economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), general volunteer time is not recognised.

On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the charity which is the amount the charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

f) Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity: this is normally upon notification of the interest paid or payable by the bank.

g) Funds accounting

Unrestricted funds are available to spend on activities that further any of the purposes of the charity. Designated funds are unrestricted of the charity which the trustees have decided at their discretion to set aside to use for a specific purpose. Restricted funds are donations which the donor has specified are to be solely used for particularly areas of the charity's work or for specific projects being undertaken by the charity.

h) Expenditure and irrecoverable VAT

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

i) Allocation of support costs

Support costs are those functions that assist the work of the charity but do not directly undertake charitable activities. Governance costs are the costs associated with the governance arrangements of the charity, including the costs of complying with constitutional and statutory requirements and any costs associated with the strategic management of the charity’s activities. These costs have been allocated between cost of raising funds and expenditure on charitable activities based on the proportion of staff time occupied by each activity as follows:

2025 2024
Raising funds 11% 14%
Charitable activities
Helpline & support services 60% 57%
Information services 25% 25%
Research 4% 4%

34

Endometriosis UK

Notes to the financial statements

For the year ended 31 March 2025

1. Accounting policies (continued)

j) Tangible fixed assets

Depreciation is provided at rates calculated to write down the cost of each asset to its estimated residual value over its expected useful life. The depreciation rates in use are as follows:

Office equipment Furniture and fittings

4 years straight line 10 years straight line

Items of equipment are capitalised where the purchase price exceeds £1,000.

k) Debtors

Trade and other debtors are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

l) Cash at bank and in hand

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

m) Creditors

Creditors and provisions are recognised where there is a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

n) Financial instruments

The charitable company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently recognised at amortised cost using the effective interest method.

o) Pension costs

The company operates a defined contribution pension scheme for its employees. There are no further liabilities other than that already recognised in the SOFA.

p) Operating leases

Rentals paid under operating leases are charged to the statement of financial activities as they fall due.

q) Foreign currency transactions

Transactions in foreign currencies are translated at rates prevailing at the date of the transaction. Balances denominated in foreign currencies are translated at the rate of exchange prevailing at the year end.

35

Endometriosis UK

Notes to the financial statements

For the year ended 31 March 2025

1. Accounting policies (continued) r) Accounting estimates and key judgements

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

The key sources of estimation uncertainty that have a significant effect on the amounts recognised in the financial statements are depreciation as described in note j above.

2. Prior period restatement

3. Prior period comparatives: statement of financial activities (restated)

Income from:
Donations and legacies
Charitable activities
Other trading activities
Investments
Total income
Expenditure on:
Raising funds
Charitable activities
Helpline and support services
Information services
Research
Total expenditure
Net income and net movement in funds		 2024
Restricted
Total
£
£
£
-
464,641
464,641
282,624
-
282,624
-
453,449
453,449
-
19,016
19,016
282,624
937,106
1,219,730
-
192,569
192,569
282,386
348,266
630,652
-
313,174
313,174
-
30,674
30,674
282,386
884,683
1,167,069
238
52,423
52,661
Unrestricted

36

Endometriosis UK

Notes to the financial statements

For the year ended 31 March 2025

4. Income from donations and legacies

Donations
Legacies
Gift in kind
Total income from donations and legacies		 2025
£
499,071
146,448
16,898
662,417		 Restated
2024
£
417,808
30,249
16,584
464,641

All income from donations and legacies in the current and prior period was unrestricted.

5. Income from charitable activities

Grants:
DHSC
Lottery Community Funding - Wales
Bloomberg LP
Simply Health
EUmetriosis
Westfield Health
Pilkington Trust
Hospital Saturday Fund
Lottery Community Funding - Scotland
Section 10 Scottish Government
Sense Foundation
Research:
University of Aberdeen
Total income from charitable activities		 2025
£
94,720
58,953
54,925
25,000
5,952
5,000
3,000
2,000
-
-
-
8,434
257,984		 2024
£
86,331
56,486
53,000
-
-
-
-
-
42,103
24,367
20,337
-
282,624

All income from charitable activites in the current and prior period was restricted.

37

Endometriosis UK

Notes to the financial statements

For the year ended 31 March 2025

6. Income from other trading activities

Income from other trading activities
Challenge events
Membership fees
Licence fees
Other fundraising activities
Total income from other trading activities		 2025
£
368,859
17,788
36,996
138,325
561,968		 Restated
2024
£
267,110
17,034
30,349
138,956
453,449

All income from other trading activities in the current and prior period was unrestricted.

7. Government grants

The charitable company receives government grants, defined as funding from the Department of Health and Social Care, the Scottish Government and the National Lottery Community Funding (Scotland and Wales), to fund charitable activities. The total value of such grants in the period ending 31 March 2025 was £153,673 (2024: £209,287). There are no unfulfilled conditions or contingencies attaching to these grants in 2024/25.

38

Endometriosis UK

Notes to the financial statements

For the year ended 31 March 2025

8. Total expenditure

Staff costs (note 10)
Information
Membership EFE
Fundraising and challenge events
Office costs
Premises costs
Professional fees
Helpline & volunteer costs
Other costs
Bad debt
Sub-total
Allocation of support costs
Allocation of governance costs
Total expenditure		 Raising funds
£
98,722
-
-
59,138
8,160
-
-
-
-
35,396
201,416
18,874
4,292
224,582		 Helpline and
support
services
Information
services
Research
£
£
£
523,117
213,183
31,193
-
61,061
-
2,436
-
-
-
-
-
57,209
67,534
1,486
-
-
-
-
-
-
72,301
-
-
2,027
3,293
-
-
-
-
657,090
345,071
32,679
100,014
40,758
5,964
22,742
9,268
1,356
779,846
395,097
39,999
Charitable activities		 Helpline and
support
services
Information
services
Research
£
£
£
523,117
213,183
31,193
-
61,061
-
2,436
-
-
-
-
-
57,209
67,534
1,486
-
-
-
-
-
-
72,301
-
-
2,027
3,293
-
-
-
-
657,090
345,071
32,679
100,014
40,758
5,964
22,742
9,268
1,356
779,846
395,097
39,999
Charitable activities		 Governance
costs
£
7,040
-
-
-
545
-
24,619
-
5,454
-
37,658
-
(37,658)
-		 Support costs
£
7,066
-
-
-
50,826
54,009
53,106
-
603
-
165,610
(165,610)
-
-		 2025 Total
£
880,321
61,061
2,436
59,138
185,760
54,009
77,725
72,301
11,377
35,396
Helpline and
support
services
£
523,117
-
2,436
-
57,209
-
-
72,301
2,027
-
657,090
100,014
22,742
779,846		 Information
services
£
213,183
61,061
-
-
67,534
-
-
-
3,293
-
345,071
40,758
9,268
395,097
1,439,524
-
-
1,439,524

39

Endometriosis UK

Notes to the financial statements

For the year ended 31 March 2025

8. Total expenditure Prior period comparative

Prior period comparative
Staff costs (note 10)
Information
Membership EFE
Fundraising and challenge events
Office costs
Premises costs
Professional fees
Helpline & volunteer costs
Other costs
Sub-total
Allocation of support costs
Allocation of governance costs
Total expenditure		 Raising funds
£
96,706
-
-
65,425
2,780
-
-
-
-
164,911
25,522
2,136
192,569		 Helpline and
support
services
Information
services
Research
£
£
£
380,867
166,785
23,639
-
39,399
-
174
-
-
-
-
-
50,890
56,063
62
-
-
-
-
-
-
86,578
-
-
4,015
3,778
-
522,524
266,025
23,701
99,962
43,601
6,381
8,166
3,548
592
630,652
313,174
30,674
Charitable activities		 Helpline and
support
services
Information
services
Research
£
£
£
380,867
166,785
23,639
-
39,399
-
174
-
-
-
-
-
50,890
56,063
62
-
-
-
-
-
-
86,578
-
-
4,015
3,778
-
522,524
266,025
23,701
99,962
43,601
6,381
8,166
3,548
592
630,652
313,174
30,674
Charitable activities		 Governance
costs
£
9,806
-
-
-
1,320
-
2,614
-
702
14,442
-
(14,442)
-		 Support costs
£
14,044
-
-
-
57,286
44,134
54,823
-
5,179
175,466
(175,466)
-
-		 2024 Total
£
691,847
39,399
174
65,425
168,401
44,134
57,437
86,578
13,674
Helpline and
support
services
£
380,867
-
174
-
50,890
-
-
86,578
4,015
522,524
99,962
8,166
630,652		 Information
services
£
166,785
39,399
-
-
56,063
-
-
-
3,778
266,025
43,601
3,548
313,174
1,167,069
-
-
1,167,069

40

Endometriosis UK

Notes to the financial statements

For the year ended 31 March 2025

9. Net movement in funds

This is stated after charging:

Depreciation
Operating lease payments
Trustees' remuneration
Trustees' reimbursed expenses
Auditors' remuneration (excluding VAT):
Statutory audit
Other services		 2025
£
10,773
34,684
Nil
308
8,800
1,520		 2024
£
12,543
48,772
Nil
564
8,400
1,360

Trustee expenses represents the payment of reimbursement of travel and subsistence costs totalling £308 (2024: £564) incurred by two trustees (2024: one) relating to attendance at meetings.

In common with other charities of our size and nature we use our auditors to assist with the preparation of the financial statements and to prepare and submit returns to the tax authorities.

10. Staff costs and numbers

Staff costs were as follows:

Salaries and wages
Social security costs
Pension costs
Employees earning more than £60,000 during the year:
Between £60,000 and £70,000		 2025
£
775,676
73,389
31,256
880,321
2025
No.
1		 2024
£
613,579
56,426
21,842
691,847
2024
No.
-

The key management personnel of the charitable company comprise the Trustees and Chief Executive Officer. The total employee benefits of the key management personnel were £72,953 (2024: £60,507).

Average head count 2025
No.
23		 2024
No.
20

41

Endometriosis UK

Notes to the financial statements

For the year ended 31 March 2025

10. Staff costs and numbers (continued)

Staff are split across activities of the charity as follows (full time equivalent basis):

Raising funds
Helpline and support services
Information services
Research
Governance		 2025
No.
2
12
5
1
-
20		 2024
No.
2
9
4
1
1
17

11. Taxation

The charity is exempt from corporation tax as all its income is charitable and is applied for charitable purposes.

12. Tangible fixed assets
Group and Charity
Cost
At 1 April 2024
Additions in year
At 31 March 2025
Depreciation
At 1 April 2024
Charge for the year
At 31 March 2025
Net book value
At 31 March 2025
At 31 March 2024		 £
23,079
29,893
52,972
3,345
2,947
6,292
46,680
19,734
Furniture &
fittings		 £
42,326
-
42,326
27,643
7,826
35,469
6,857
14,683
Office
equipment		 Total
£
65,405
29,893
95,298
30,988
10,773
41,761
53,537
34,417

42

Endometriosis UK

Notes to the financial statements

For the year ended 31 March 2025

13. Subsidiary undertakings

Endometriosis UK Trading Limited

Endometriosis UK Trading Limited was incorporated in the UK as a wholly owned subsidiary of Endometriosis UK on 2 June 2006 (company no. 05836007), with an issued share capital of £1.

Turnover
Cost of sales
Gross profit
Administrative expenses
Operating profit
Interest receivable
Interest payable
Loss on ordinary activities
Corporation tax
Gift aid to parent undertaking
Loss for financial year
The aggregate of the assets, liabilities and funds was:
Assets
Liabilities
Funds		 2025
£
35,396
-
35,396
(35,430)
(34)
3
(60)
(91)
-
-
(91)
2025
£
1,823
(71)
1,752		 2024
£
-
-
-
(1,035)
(1,035)
3
-
(1,032)
-
-
(1,032)
2024
£
1,843
-
1,843

14. Parent charity

The parent charity's gross income and the results for the year are disclosed as follows:

Gross income
Results for the year		 2025
£
1,471,448
67,415		 2024
£
1,219,727
53,693

43

Endometriosis UK

Notes to the financial statements

For the year ended 31 March 2025

15. Debtors

Trade debtors
Prepayments
Accrued income
VAT
Amounts owed by group undertakings		 2025
2024
£
£
20,397
23,970
1,282
2,396
9,948
13,533
1,149
-
-
-
32,776
39,899
The group		 2025
2024
£
£
20,397
23,970
1,282
2,396
9,948
13,339
1,149
-
71
-
32,847
39,705
The charity		 2025
2024
£
£
20,397
23,970
1,282
2,396
9,948
13,339
1,149
-
71
-
32,847
39,705
The charity
39,705

16. Creditors: amounts falling due within 1 year

Trade creditors
Taxation and social security
Deferred income (note 17)
Accruals
Amounts owed to group undertakings
Other creditors
Deferred income
Deferred during the year		 2025
2024
£
£
17,792
61,125
22,154
18,068
119,393
-
10,980
11,965
-
-
4,867
3,113
175,186
94,271
2025
2024
£
£
119,393
-
The group
The group		 2025
2024
£
£
17,792
61,125
22,154
18,068
119,393
-
10,980
11,965
-
213
4,867
3,113
175,186
94,484
2025
2024
£
£
119,393
-
The charity
The charity

17. Deferred income

Deferred income relates to a pre-financing float held for the EUmetriosis project.

44

Endometriosis UK

Notes to the financial statements

For the year ended 31 March 2025

For the year ended 31 March 2025
18. Analysis of group net assets between funds
£
Tangible fixed assets
-
Current assets
161,655
Current liabilities
(119,393)
Net assets at 31 March 2025
42,262
Prior year comparative
£
Tangible fixed assets
-
Current assets
97,404
Current liabilities
-
Net assets at 31 March 2024
97,404
Restricted
funds
Restricted
funds		 £
-
317,333
-
317,333
£
-
238,000
-
238,000
Designated
funds
Designated
funds		 £
53,537
1,064,292
(55,793)
1,062,036
£
34,417
1,078,757
(94,271)
1,018,903
General
funds
General
funds		 Total
funds
£
53,537
1,543,280
(175,186)
1,421,631
Total
funds
£
34,417
1,414,161
(94,271)
1,354,307

45

Endometriosis UK

Notes to the financial statements

For the year ended 31 March 2025

19. Movements in group funds

Movements in group funds
At 1 April
2024
£
Restricted funds
Lottery Community
Funding - Scotland
19,514
Lottery Community
Funding - Wales
36,231
Sense Foundation Grant
13,804
DHSC Grant
-
Bloomberg LP
27,855
Simply Health
-
EUmetriosis
-
Westfield Health
-
Pilkington Trust
-
Hospital Saturday Fund
-
Total restricted funds
97,404
Unrestricted funds
Designated funds:
Webchat and Helpline
Expansion
94,000
Additional Scottish
Project
40,000
Diversity & Inclusion
Activities
104,000
Nurse-led Support Line
-
Total designated funds
238,000
General funds
1,018,903
Total unrestricted funds
1,256,903
Total funds
1,354,307		 Income
£
-
58,953
-
94,720
54,925
25,000
5,952
5,000
3,000
2,000
249,550
-
-
-
-
-
1,257,298
1,257,298
1,506,848		 £
(19,514)
(64,971)
(13,804)
(94,720)
(70,731)
(25,000)
(5,952)
(5,000)
(3,000)
(2,000)
(304,692)
(94,000)
(40,000)
(52,000)
-
(186,000)
(948,832)
(1,134,832)
(1,439,524)
Expenditure		 £
-
-
-
-
-
-
-
-
-
-
-
-
-
-
265,333
265,333
(265,333)
-
-
Transfers
between
funds		 £
-
30,213
-
-
12,049
-
-
-
-
-
At 31 March
2025
42,262
-
-
52,000
265,333
317,333
1,062,036
1,379,369
1,421,631

Purposes of restricted funds

Lottery Community Funding for expanding and strengthening support groups in Scotland, Funding - Scotland increasing the awareness and availability of our Helpline, Webchat and information resources, and appointing a Scotland-based staff member to deliver the above.

Lottery Community Funding for expanding and strengthening support groups in Wales, Funding - Wales increasing the awareness and availability of our helpline, web chat and information resources, and appointing a Wales-based staff member to deliver the above.

46

Endometriosis UK

Notes to the financial statements

For the year ended 31 March 2025

19. Movements in group funds (continued) Purposes of restricted funds (continued)

Sense Foundation Grant Funding for the Support and Information project, recruiting and training helpline and webchat volunteers, reviewing and developing information and increasing helpline and web chat provision.

DHSC Grant Funding to develop a workplace menstrual wellbeing programme, developing and providing information and guidance on a range of menstrual conditions to SME's and providing SME's with targeted information events, webinars, resources and downloadable information.

Bloomberg LP Funding to deliver awareness and understanding of Endometriosis to various EDI communities over three years.

Simply Health A one-off grant to go towards the opening of the new Specialist Nurse helpline.

Westfield Health A one-off grant to launch an endometriosis symptom checker on our website.

Purpose of designated funds

This funded the ongoing support, development and expansion of the web chat and helpline services and was fully spent in the year.

Additional Scottish Project

This funded additional services in Scotland and was fully spent in the year.

Diversity & Inclusion We had identified that we had less reach within certain communities, Activities notably those from black, Asian and minority ethnic and LGBTQ+ communities. Additional funding was allocated to increase capacity in this area, undertake research and deliver improved reach. This will be fully spent next year.

Nurse-led Support Line Funds were set aside at the start of the year for a nurse-led support line, to complement our volunteer peer–led helpline, to be spent over three years.

47

Endometriosis UK

Notes to the financial statements

For the year ended 31 March 2025

19. Movements in group funds (continued) Transfers between funds

The transfers between designated funds and general funds are explained in the narratives above.

Prior year comparative

At 1 April
2023
£
Restricted funds
Alliance - Scottish Grant
9,971
Lottery Community
Funding - Scotland
23,111
Lottery Community
Funding - Wales
29,994
Intuitive Grant
6,800
Access Group
Foundation Grant
5,637
Sense Foundation Grant
17,250
DHSC Grant
-
Blackbaud Grant
4,403
Section 10 Scottish
Government
-
Bloomberg LP
-
Total restricted funds
97,166
Unrestricted funds
Designated funds:
Webchat and Helpline
Expansion
140,000
Additional Scottish
Project
40,000
Diversity & Inclusion
Activities
156,000
Total designated funds
336,000
General funds
868,480
Total unrestricted funds
1,204,480
Total funds
1,301,646		 Income
£
-
42,103
56,486
-
-
20,337
86,331
-
24,367
53,000
282,624
-
-
-
-
937,106
937,106
1,219,730		 £
(9,971)
(45,700)
(50,249)
(6,800)
(5,637)
(23,783)
(86,331)
(4,403)
(24,367)
(25,145)
(282,386)
(46,000)
-
(52,000)
(98,000)
(786,683)
(884,683)
(1,167,069)
Expenditure		 £
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Transfers
between
funds		 £
-
19,514
36,231
-
-
13,804
-
-
-
27,855
At 31 March
2024
97,404
94,000
40,000
104,000
238,000
1,018,903
1,256,903
1,354,307

48

Endometriosis UK

Notes to the financial statements

For the year ended 31 March 2025

20. Operating lease commitments

The group and charity had operating leases at the year end with total future minimum lease payments as follows:

payments as follows:
Amount falling due:
Within 1 year
Within 1 - 5 years		 2025
2024
£
£
49,390
7,508
115,243
-
164,633
7,508
The group		 2025
2024
£
£
49,390
7,508
115,243
-
164,633
7,508
The charity
7,508

21. Related party transactions

Endometriosis UK has a wholly owned subsidiary Endometriosis UK Trading Limited, a company limited by shares (company no. 05836007). At 31 March 2025, Endometriosis UK Trading Limited owed Endometriosis UK £71 (2024: Endometriosis UK owed Endometriosis UK Trading Limited £213).

The charity received unrestricted donations totalling £100 (2024: £860) from one trustee (2024: four) during the year. There are no unfulfilled conditions attached to these donations.

49